Avanafil-13CD3 is a deuterated form of avanafil, a selective phosphodiesterase type 5 (PDE5) inhibitor primarily used for the treatment of erectile dysfunction. The deuterated version, indicated by the "13CD3" in its name, incorporates deuterium, a stable isotope of hydrogen, which can enhance the pharmacokinetic properties of the compound, potentially affecting its metabolism and bioavailability. Avanafil works by increasing blood flow to the penis in response to sexual stimulation, facilitating an erection. The compound is characterized by its rapid onset of action and relatively short half-life compared to other PDE5 inhibitors. Its chemical structure includes a pyrazolopyrimidinone core, which is essential for its biological activity. Avanafil is generally well-tolerated, with common side effects including headache, flushing, and nasal congestion. The specific characteristics of Avanafil-13CD3, including its stability, solubility, and interaction with biological systems, may differ from the non-deuterated form, making it a subject of interest in pharmacological research.

Avanafil-13CD3

2738376-89-9: Avanafil-13CD3 is a deuterated form of avanafil, a selective phosphodiesterase type 5 (PDE5) inhibitor primarily used for the treatment of erectile dysfunction. The deuterated version, indicated by the "13CD3" in its name, incorporates deuterium, a stable isotope of hydrogen, which can enhance the pharmacokinetic properties of the compound, potentially affecting its metabolism and bioavailability. Avanafil works by increasing blood flow to the penis in response to sexual stimulation, facilitating an erection. The compound is characterized by its rapid onset of action and relatively short half-life compared to other PDE5 inhibitors. Its chemical structure includes a pyrazolopyrimidinone core, which is essential for its biological activity. Avanafil is generally well-tolerated, with common side effects including headache, flushing, and nasal congestion. The specific characteristics of Avanafil-13CD3, including its stability, solubility, and interaction with biological systems, may differ from the non-deuterated form, making it a subject of interest in pharmacological research.

CAS 2738376-89-9

Avanafil-13CD3

Avanafil-13C-d3

Ref: 4Z-A-292